|Awarded On||February 18, 2015|
|Title||Translational Investigations On Fenretinide and Safingol For Pediatric Cancer Use|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Texas Tech University Health Sciences Center|
|Principal Investigator/Program Director||Barry J Maurer|
|Cancer Sites||Childhood and Adolescent|
We are developing a new kind of chemotherapy to fight pediatric cancers resistant to current therapies. This new chemotherapy uses high doses of a drug, called fenretinide, to increase certain toxic waxes, called dihydroceramides, in cancer cells and kill them. Because these waxes do not increase in normal cells, fenretinide is well-tolerated clinically. Using new formulations of fenretinide, we have been able to reduce, even eliminate, pediatric neuroblastoma cancer cells in some children in early clinical trials. We will now try to further increase the killing power of fenretinide by combining it with an artificial wax, called safingol. In the laboratory, when fenretinide-induced waxes mee...